Outlook Therapeutics (OTLK) has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. In her role as Vice President of Corporate Strategy and Business Development, Ms. Cantrell will be responsible for leading Outlook Therapeutics’ business development strategy, including strategic partnerships, licensing opportunities and corporate development initiatives. Cantrell brings more than 20 years of experience in global corporate strategy, business development, and portfolio leadership across the biotechnology and pharmaceutical industries and is a seasoned biotech executive with deep expertise in business development, commercial strategy, and global portfolio expansion.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Largest borrow rate increases among liquid names
- The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics
- Outlook Therapeutics price target lowered to $1 from $3 at Chardan
- Outlook Therapeutics price target lowered to 50c from $1 at H.C. Wainwright
- Morning Movers: Baidu jumps following proposed spinoff of Kunlunxin